Supriya Lifescience Limited Approves FY26 Results and Recommends Final Dividend

Supriya Lifescience Limited Approves FY26 Results and Recommends Final Dividend​

Supriya Lifescience Limited announced the outcome of its Board of Directors meeting held on May 27, 2026. The Board reviewed and approved the audited financial results for the Quarter and the full year ended March 31, 2026. Furthermore, the Directors recommended a final dividend, subject to shareholder approval at the ensuing Annual General Meeting.

The company's financial reports provided comprehensive data on performance, balance sheet positions, and cash generation for the fiscal year 2026 compared to 2025.

Dividend Recommendation​

At the board meeting on May 27, 2026, the Directors recommended a final dividend of Re. 1.00 (Rupee 1.00) per equity share. This represents 50% of the face value of the share, which stands at Rs. 2/- each.

Financial Performance Summary​

The audited financial results provide a comparative look at the company’s performance. Total Income for the year ended March 31, 2026, was 8,393.62 Indian million, up from 7,063.00 Indian million in the previous year. The profit for the period from continuing operations was 2,091.20 Indian million.

Total Comprehensive Income for the period also showed a significant increase, reaching 2,090.21 Indian million for the year ended March 31, 2026, compared to 1,878.33 Indian million the previous year. Earnings per equity share for continuing operations stood at 25.98 Indian million for the financial year 2026, compared to 23.35 Indian million in 2025.

For a detailed comparison of key financial metrics, the following table summarizes the annual data:

Balance Sheet Overview​

The Standalone Balance Sheet as of March 31, 2026, showed the total assets reaching 13,571.07 Indian million, compared to 11,173.47 Indian million on the same date in 2025.

The company’s total equity increased to 11,977.33 Indian million, while total liabilities were 1,593.74 Indian million.

Cash Flow Analysis​

Analysis of the Cash Flow Statement reveals strong operational cash generation. Net Cash generated from Operating Activities (A) for the year ended March 31, 2026, was 1,857.69 Indian million, an increase from 1,646.75 Indian million in 2025.

The net cash generated/(outflow) from Investing Activities was (1,761.74) Indian million for the year ending March 31, 2026, primarily driven by purchases of fixed assets amounting to (1,522.35) Indian million.

The overall net increase in cash and cash equivalents for the period was (2.87) Indian million, resulting in cash and cash equivalents at the end of the reporting period of 788.67 Indian million.

SUPRIYA Stock Price Movement​

Today, Supriya Lifescience Limited shares edged higher to close at ₹807.25, gaining 3.85% in after-hours trading. The stock traded within a range today, touching a high of ₹818 and logging a solid volume of 532,518 shares.